Sort
4,870 grants matching “glp 1”
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle
$727,601Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2020 · HD
Saracatinib and 1400W Counteract Nerve Agents-induced Long-term Neurotoxicity
$727,305Thimmasettappa Thippeswamy · Iowa State University · U01 · FY2021 · NS
Cost-Effectiveness of Food is Medicine Interventions to Improve Diet and Reduce Cardiometabolic Diseases
$726,754Dariush Mozaffarian · Tufts University Boston · R01 · FY2025 · HL
Affordable oral delivery of human blood protein drugs bioencapsulated in plant cells
$726,730Henry Daniell · University Of Pennsylvania · R01 · FY2019 · HL
The Effects of Neprilysin Inhibition on Cardiometabolic Health in Black Individuals
$725,614Pankaj Arora · University Of Alabama At Birmingham · R01 · FY2023 · HL
Regulation of the biosynthesis of a novel class of anti-diabetic lipids
$725,577Barbara B Kahn · Beth Israel Deaconess Medical Center · R01 · FY2016 · DK
Obesity complicating type 1 diabetes in young people: Physiology and Impact of GLP-1 analogue anti-obesity treatment on cardiometabolic risk factors
$725,290Michelle Van Name · Yale University · R01 · FY2025 · DK
The Effects of Neprilysin Inhibition on Cardiometabolic Health in Black Individuals
$725,178Pankaj Arora · University Of Alabama At Birmingham · R01 · FY2024 · HL
Obesity complicating type 1 diabetes in young people: Physiology and Impact of GLP-1 analogue anti-obesity treatment on cardiometabolic risk factors
$723,984Michelle Van Name · Yale University · R01 · FY2023 · DK
Novel Small Molecule Therapeutics to Treat Obesity
$723,900Susan Medghalchi · Fasgen, Inc. · R44 · FY2010 · DK
Novel Small Molecule Therapeutics to Treat Obesity
$723,900Susan Medghalchi · Fasgen, Inc. · R44 · FY2009 · DK
Antithrombotic Therapy with No Bleeding Risk for PCI
$723,518Ridong Chen · Apt Therapeutics, Inc. · R44 · FY2019 · HL
Clinical Development of Elafin as a PAH Therapy
$723,280Roham Zamanian · Stanford University · P01 · FY2021 · HL
Clinical Development of Elafin as a PAH Therapy
$723,280Roham Zamanian · Stanford University · P01 · FY2020 · HL
Clinical Trials and Ancillary Assays
$722,307Harriet L Robinson · Geovax, Inc. · U19 · FY2009 · AI
Clinical Development of Elafin as a PAH Therapy
$721,906Roham Zamanian · Stanford University · P01 · FY2019 · HL
Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons
$721,831Robert Mehalso · Sensodx Ii, Llc · R42 · FY2020 · DA
Effects of bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity
$719,472Melanie Schorr Haines · Massachusetts General Hospital · R01 · FY2023 · DK
Human antibodies for therapeutic intervention of staph enterotoxin B exposure
$719,213Luigi Grasso · Morphotek, Inc. · U01 · FY2008 · AI
B. thuringiensis crystal proteins as powerful next-generation anthelmintics
$719,185Raffi V Aroian · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · AI
Translational feasibility of an oral, non-hormonal, male contraceptive pill
$719,059Paul D Crowe · Orphagen Pharmaceuticals · R44 · FY2020 · HD
Development of an inhibitor of VEGF expression
$719,008Ptc Therapeutics, Inc. · R44 · FY2005 · CA
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent For Diagnosis of Renal Failure
$717,997Balaji Sitharaman · Theragnostic Technologies, Inc. · R44 · FY2016 · DK
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
$717,432George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2024 · AI
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment
$716,879Adnan Ismail Dibas · Nanoscope Technologies, Llc · R44 · FY2022 · EY